Moreover, the 36-month beta value for RCKT is 1.02. Analysts have varying opinions on the stock, with 12 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RCKT is 98.65M and currently, short sellers hold a 11.39% of that float. On February 28, 2025, RCKT’s average trading volume was 1.46M shares.
RCKT) stock’s latest price update
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s stock price has dropped by -1.26 in relation to previous closing price of 9.52. Nevertheless, the company has seen a loss of -13.52% in its stock price over the last five trading days. businesswire.com reported 2025-02-27 that CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2024. “In 2024, we made strong progress in advancing our gene therapy pipeline, underscored by the New England Journal of Medicine publication of the Phase 1 study of.
RCKT’s Market Performance
RCKT’s stock has fallen by -13.52% in the past week, with a monthly drop of -11.15% and a quarterly drop of -33.38%. The volatility ratio for the week is 6.44% while the volatility levels for the last 30 days are 5.34% for Rocket Pharmaceuticals Inc. The simple moving average for the past 20 days is -9.24% for RCKT’s stock, with a -45.32% simple moving average for the past 200 days.
Analysts’ Opinion of RCKT
Many brokerage firms have already submitted their reports for RCKT stocks, with Wedbush repeating the rating for RCKT by listing it as a “Outperform.” The predicted price for RCKT in the upcoming period, according to Wedbush is $32 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $29. The rating they have provided for RCKT stocks is “Buy” according to the report published on December 18th, 2024.
RCKT Trading at -14.35% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.13% of loss for the given period.
Volatility was left at 5.34%, however, over the last 30 days, the volatility rate increased by 6.44%, as shares sank -9.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.22% lower at present.
During the last 5 trading sessions, RCKT fell by -13.52%, which changed the moving average for the period of 200-days by -59.71% in comparison to the 20-day moving average, which settled at $10.36. In addition, Rocket Pharmaceuticals Inc saw -25.22% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from Schwartz Jonathan David, who sale 6,532 shares at the price of $10.58 back on Feb 25 ’25. After this action, Schwartz Jonathan David now owns 237,638 shares of Rocket Pharmaceuticals Inc, valued at $69,109 using the latest closing price.
Schwartz Jonathan David, the of Rocket Pharmaceuticals Inc, sale 2,754 shares at $23.35 during a trade that took place back on May 17 ’24, which means that Schwartz Jonathan David is holding 169,659 shares at $64,306 based on the most recent closing price.
Stock Fundamentals for RCKT
Current profitability levels for the company are sitting at:
- -26.55 for the present operating margin
- 0.05 for the gross margin
The net margin for Rocket Pharmaceuticals Inc stands at -25.03. The total capital return value is set at -0.77. Equity return is now at value -59.27, with -52.01 for asset returns.
Based on Rocket Pharmaceuticals Inc (RCKT), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -7.49. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -145.4.
Currently, EBITDA for the company is -236.62 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 93.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.05.
Conclusion
To wrap up, the performance of Rocket Pharmaceuticals Inc (RCKT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
